Literature DB >> 26024102

Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration.

Gabriel Coscas1, Marco Lupidi2, Florence Coscas1, Fayçal Benjelloun3, Jennifer Zerbib3, Ali Dirani4, Oudy Semoun3, Eric H Souied3.   

Abstract

PURPOSE: To suggest a clinical distinction between idiopathic polypoidal choroidal vasculopathy (PCV) and secondary polyps associated with neovascular age-related macular degeneration (NV-AMD).
METHODS: The study was a retrospective case series of 52 eyes of 52 consecutive patients (31 females and 21 males) diagnosed with PCV. Initial diagnosis was based on scanning laser ophthalmoscope-indocyanine green angiography (SLO-ICGA) in association with fluorescein angiography (FA) and optical coherence tomography (OCT). All the data and images were analyzed in a masked fashion by four experienced examiners in two different sessions: the first, to classify patients into the two hypothesized groups (idiopathic polyps or NV-AMD-related polyps); the second, following a predetermined scheme, to describe objective features. The results obtained in each session underwent a cross multivariate analysis to identify statistically significant differences (P ≤ 0.05) between the two groups.
RESULTS: The two groups were clinically different on the basis of FA (leakage origin [P = 0.001] and presence of drusen [P = 0.001]), ICGA (evidence of choroidal neovascularization [CNV; P = 0.001] and/or branching vascular network [BVN; P = 0.001]), OCT imaging (type of pigmented epithelium detachment [P = 0.001], presence of BVN [P = 0.001], and subfoveal choroidal thickness [P = 0.001]). Further significant differences were observed according to the location of lesion (uni- or multifocal) (P = 0.001), type of CNV (P = 0.001), and best-corrected visual acuity (P = 0.001).
CONCLUSIONS: Our study demonstrated clinical and statistically significant differences between idiopathic PCV and NV-AMD-related polyps that could be considered as distinct entities. Although they share some similarities, mainly the sub-RPE location, the ability to identify a specific clinical pattern suggests a more specific therapeutic approach for these two entities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26024102     DOI: 10.1167/iovs.14-16236

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  28 in total

1.  Analysis of choroidal morphology and comparison of imaging findings of subtypes of polypoidal choroidal vasculopathy: a new classification system.

Authors:  Zi-Yang Liu; Bing Li; Song Xia; You-Xin Chen
Journal:  Int J Ophthalmol       Date:  2020-05-18       Impact factor: 1.779

2.  Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy.

Authors:  Sandeep Kumar; Hiroyuki Nakashizuka; Alex Jones; Alyssia Lambert; Xuchen Zhao; Megan Shen; Mackenzie Parker; Shixian Wang; Zachary Berriochoa; Amrita Fnu; Stephanie VanBeuge; Patricia Chévez-Barrios; Mark Tso; Jon Rainier; Yingbin Fu
Journal:  Am J Pathol       Date:  2017-09-21       Impact factor: 4.307

Review 3.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

4.  Choroidal morphology and short-term outcomes of combination photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Jiwon Baek; Jae Hyung Lee; Sohee Jeon; Won Ki Lee
Journal:  Eye (Lond)       Date:  2018-10-10       Impact factor: 3.775

5.  Polypoidal Choroidal Vasculopathy after Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: A Case Report with Long-Term Follow-Up.

Authors:  Alexandra Steinemann; Laura Hoffmann; Katja B Hatz
Journal:  Case Rep Ophthalmol       Date:  2021-04-30

6.  Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome.

Authors:  Wing H Chung; Elon H C van Dijk; Danial Mohabati; Greet Dijkman; Suzanne Yzer; Eiko K de Jong; Sascha Fauser; Reinier O Schlingemann; Carel B Hoyng; Camiel J F Boon
Journal:  Clin Ophthalmol       Date:  2016-12-21

7.  Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Authors:  Keiko Azuma; Atsushi Okubo; Yoko Nomura; Hanpeng Zhou; Ryo Terao; Yohei Hashimoto; Kimiko Shimizu Asano; Kunihiro Azuma; Tatsuya Inoue; Ryo Obata
Journal:  Sci Rep       Date:  2020-05-20       Impact factor: 4.379

8.  Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study.

Authors:  Shinichi Sakamoto; Hidenori Takahashi; Yuji Inoue; Yusuke Arai; Satoru Inoda; Natsuko Kakinuma; Yujiro Fujino; Tatsuro Tanabe; Hidetoshi Kawashima; Yasuo Yanagi
Journal:  Clin Ophthalmol       Date:  2018-06-25

Review 9.  Characteristics of Pachychoroid Diseases and Age-Related Macular Degeneration: Multimodal Imaging and Genetic Backgrounds.

Authors:  Kenji Yamashiro; Yoshikatsu Hosoda; Masahiro Miyake; Sotaro Ooto; Akitaka Tsujikawa
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

10.  Microperimetry and multimodal imaging in polypoidal choroidal vasculopathy.

Authors:  Jennifer H Acton; Ken Ogino; Yumiko Akagi; John M Wild; Nagahisa Yoshimura
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.